Risk factors
Microbot Medical (MBOT) risk factors
Item 1A of every Microbot Medical Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors41 risks4 new6 dropped10 reworded
Microbot transitioned from a research-stage company to commercializing its sole product, the LIBERTY Endovascular Robotic Surgical System.
Filed Mar 26, 2026 - FY2024 10-K risk factors43 risks
Microbot operates as an early-stage medical device company facing continuous operating losses and dependence on the LIBERTY system. Operations and key personnel are heavily concentrated in Israel, creating regional geopolitical and military vulnerabilities. Intellectual property protection, regulatory approvals from the FDA and foreign bodies, and third-party manufacturing partnerships are critical to future commercialization.
Filed Mar 25, 2025